Lupin Limited (LUPIN) makes its debut in Dow Jones Best-in-Class Indices 2026, highlighting its strong ESG performance and commitment to sustainability.
GPT Healthcare Limited (NSE: GPTHEALTH) reported a 24.30% y-o-y revenue growth for Q4 FY26, reaching Rs. 128.0 crore.
Strides Pharma Science Limited (STAR) reveals robust FY26 results with a 50% YoY growth in operational PAT and a 21% rise in Ex-US markets.
Glenmark Pharmaceuticals Limited (GLENMARK) launches Vancomycin Hydrochloride for Injection in USA, expanding access to quality, affordable medicines.
Valiant Laboratories Limited (VALIANTLAB) announces its board's in-principle approval to explore restructuring options for achieving synergies.
Gland Pharma Limited (NSE: GLAND) reports record revenues and profitability with 22% YoY growth in Q4 FY26 and 97% PAT growth.
Alembic Pharmaceuticals Limited (APLLTD) Q4 FY26 results show a 4% revenue growth, with significant gains in US Formulation and strong EBITDA margin.
Sai Life Sciences Limited (SAILIFE) reports a 29% revenue increase and a 56% EBITDA rise for FY26, driven by strong execution and strategic investments.
Solara Active Pharma Sciences Limited (NSE: SOLARA) reports strong Q4’26 earnings with 40% YoY growth, driven by robust base business despite challenges in Ibuprofen segment.
Hester Biosciences Limited (HESTERBIO) to announce date for Annual General Meeting and dividend details for FY 2026.